Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Objective: To evaluate the eYcacy of the essential omega-6 fatty acid Gammalinolenic acid (GLA) on fatigue associated with primary
Sjo¨ gren’s syndrome.
Methods: Ninety patients with primary Sjo¨ gren’s syndrome (with or without signs of autoimmunity) entered a 6-month double blind
placebo-controlled randomised trial with high dose GLA (extracted from Evening Primrose Oil ) or corn oil. The primary outcome
parameter was fatigue; secondary endpoints were eye dryness, mouth dryness, muscle and joint pain.
Results: No statistically signiŽ cant improvement was found in fatigue assessed by Visual Analogue Scale (VAS) or in the time needed for
sleeping/resting during a 24-hour period. No diVerences were found between the treatment and placebo group. The same applies to the
secondary endpoints: no diVerences in VAS for eye and mouth dryness or pain, no signiŽ cant changes in Schirmer-1-test, van Bijsterveld
score, unstimulated whole sialometry (UWS), or use of artiŽ cial tears or analgesics. Only mild side eVects were observed.
Conclusion: According to our study results GLA (Evening Primrose oil ) treatment for fatigue in primary Sjo¨gren’s syndrome is ineVective.


Enheter & grupper

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Reumatologi och inflammation


Sidor (från-till)72-79
TidskriftScandinavian Journal of Rheumatology
Utgåva nummer2
StatusPublished - 2002
Peer review utfördJa